Serological survey on hepatitis E virus infection in an endemic area: diagnosis potential of enzyme immunoassay for detection of IgG antibody

Balayan, M. S.; Zamyatina, N. A.; Михайлов, М. И.; Сычев, А. В.; Usmanov, R.K.; Dvoynikova, O.V.; Nelga, I.V.; Grishina, G.K.; Ankhundinova, L.A.

doi:10.1016/0928-0197(94)90054-x

Cited by 13 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although EIAs for anti-HEV IgG and IgM are available commercially, these may have some limitations because of the window phase prior to the appearance of the antibodies [Balayan et al, 1994;Lin et al, 2000]. The ''golden standard'' for diagnosis of HEV infection should be ideally the detection of viremia, by detection of either the HEV genome or the capsid protein.…”

Section: Discussionmentioning

confidence: 98%

Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E

Zhang

Li³

et al. 2006

J. Med. Virol.

View full text Add to dashboard Cite

Infection with hepatitis E virus (HEV) may be diagnosed by the presence of HEV RNA or anti-HEV antibodies. An enzyme immunoassay (EIA) was developed for the detection of antigen. Twenty-four monoclonal antibodies (mAbs) were produced. An indirect sandwich EIA was developed to detect HEV antigen using a combination of three mAbs as coating antibodies. Approximately 44.6% (33/74), 28.6% (50/175), and none (0/27) of sera positive for anti-HEV IgM alone, both anti-HEV IgM and IgG, and anti-HEV IgG alone also were positive for HEV antigen using this EIA. Forty-two HEV antibody-positive sera were tested for HEV RNA and antigen in parallel and the concordance was 81.0% (34/42). All PCR products were found to belong to HEV genotype 4. In order to evaluate the temporal relationship between HEV antigen positivity and HEV RNA, anti-HEV IgG and IgM, and ALT concentrations, macaques were infected with HEV genotypes 1 and 4 and serial samples were collected. The results showed that the antigen EIA can detect the capsid proteins of both genotypes. HEV antigen was detectable prior to ALT elevation and the appearance of anti-HEV antibodies in the infected monkeys and lasted for several weeks in all cases. HEV antigen became detectable in the serum at almost the same time as HEV RNA in feces but persisted for 4 weeks less than HEV RNA. This assay should be valuable for the diagnosis of acute hepatitis E, particularly in the window period prior to seroconversion to anti-HEV.

show abstract

Section: Discussionmentioning

confidence: 98%

Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E

Zhang

Li³

et al. 2006

J. Med. Virol.

View full text Add to dashboard Cite

show abstract

“…Recombinant antigen-based assays have also been introduced for serological surveillance studies in selected groups of clinical patients and healthy subjects living in endemic areas [Lok et al, 1992;Balayan et al, 1994]. There are limited data on the utility of these assays for determining the epidemiology of HEV in hemodialysis patients and among healthy people in nonendemic countries.…”

Section: Discussionmentioning

confidence: 98%

“…It is now well recognized by epidemiological analysis of populations with high prevalences of anti-HEV in India [Arankalle et al, 1995], Turkey [Thomas et al, 1993], Southern Italy [Zanetti et al, 1994], the former Soviet Union [Balayan et al, 1994], and the United States [Purcell and Tsarev, 1996] that seroprevalence rises in the late teens and early adulthood, at which time the peak incidence of HEV infection is likely to occur. An age-dependent increase in seropositivity was also observed in our reference population corroborating the generality of this finding.…”

Section: Discussionmentioning

confidence: 98%

Prevalence of antibodies to hepatitis E virus among hemodialysis patients in Sweden

1998

View full text Add to dashboard Cite

In order to study the prevalence of antibody to hepatitis E virus (HEV) among hemodialysis patients and to evaluate whether chronic hemodialysis is associated with an increased risk of exposure to HEV in developed countries, the IgG anti-HEV was determined in serum samples obtained from 182 patients on chronic hemodialysis and 349 statistically selected, healthy Swedish control subjects. Serum specimens from 11 of the 182 (6.0%) hemodialysis patients and from 18 of the 349 (5.2%) control subjects were repeatedly positive for HEV antibodies (the difference was not significant: P = .67). Analysis of serial serum samples obtained at the initiation of hemodialysis and consecutively during follow-up periods of several years demonstrated no IgG anti-HEV seroconversion during chronic hemodialysis. The seroprevalence of anti-HEV antibody in the adult Swedish population was associated significantly with age. In persons younger than 40 years, the percentage of seropositive individuals was 2.5%, whereas the seroprevalence rate of anti-HEV was 7.4% in subjects older than 40 years (P < .05). This study indicates that nosocomial transmission of HEV to patients on maintenance hemodialysis was non-existent in three dialysis centers in Sweden (a developed country) and that chronic hemodialysis is not associated with an increased risk of exposure to HEV infection in this region.

show abstract

“…119 In Kyrghizstan, an area considered endemic for hepatitis E, the population seroprevalence was only 4.6%. 120 However, from 1980 to 1989, HEV was indicated as the causative agent in a significant portion of cases of acute hepatitis tested (ranging from 17-86% by location and year). 120 These results may be unreliable as cases were detected using an early version of an Abbott enzyme immunoassay (EIA) diagnostic test.…”

Section: Central Asiamentioning

confidence: 99%

Epidemiology of Hepatitis E in Low- and Middle-Income Countries of Asia and Africa

et al. 2013

View full text Add to dashboard Cite

Hepatitis E is an acute, viral hepatitis primarily transmitted through the fecal-oral route. The first major epidemic of hepatitis E virus (HEV) was reported in 1955 in Delhi, India. Since that time, numerous epidemics have been reported across the low- and middle-income countries in Asia and Africa. Even in the absence of large-scale outbreaks, hepatitis E is an important cause of clinical hepatitis. Serologic studies across Asia and Africa show a high prevalence of anti-HEV antibodies. Interest in hepatitis E has increased over the last two decades. However, there are many unanswered questions about the epidemiology of hepatitis E, including a low clinical illness rate in children and the high case fatality rate in pregnant women. Widespread usage of a hepatitis E vaccine may serve to relieve the burden of HEV disease in low- and middle-income countries in Africa and Asia.

show abstract

Serological survey on hepatitis E virus infection in an endemic area: diagnosis potential of enzyme immunoassay for detection of IgG antibody

Cited by 13 publications

References 13 publications

Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E

Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E

Prevalence of antibodies to hepatitis E virus among hemodialysis patients in Sweden

Epidemiology of Hepatitis E in Low- and Middle-Income Countries of Asia and Africa

Contact Info

Product

Resources

About